Aurinia Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.09.19	Aurinia Establishes At-the-Market Facility (Businesswire)
06.09.19	Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference (Businesswire)
06.08.19	Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights (Businesswire)
01.08.19	Aurinia Pharmaceuticals to Release Second Quarter 2019 Financial Results on August 6, 2019 (Businesswire)
18.07.19	Aurinia Announces Further Strengthening of the Senior Management Team (Businesswire)
27.06.19	Aurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting (Businesswire)
21.06.19	Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline (Businesswire)
07.06.19	Aurinia Issues Letter to Shareholders (Businesswire)
04.06.19	Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences (Businesswire)
31.05.19	Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders (Businesswire)
17.05.19	Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference (Businesswire)
14.05.19	Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights (Businesswire)
10.05.19	Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis (Businesswire)
09.05.19	Aurinia Pharmaceuticals to Release First Quarter 2019 Financial Results on May 14, 2019 (Businesswire)
30.04.19	Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen (Businesswire)
24.04.19	Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference (Businesswire)
11.04.19	Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board (Businesswire)
19.03.19	Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights (Businesswire)
14.03.19	Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease (Businesswire)
07.03.19	Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019 (Businesswire)
27.02.19	Aurinia Closes At-The-Market Facility (Businesswire)
25.02.19	Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis (Businesswire)
20.02.19	Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City (Businesswire)
22.01.19	Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome (Businesswire)
21.01.19	Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome (Businesswire)
11.01.19	9 Pharma Stocks To Watch This Month (RTTNews)
19.12.18	Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco (Businesswire)
30.11.18	Aurinia Establishes at-the-Market Facility (Businesswire)
09.11.18	Aurinia to Participate in November Investor Conferences (Businesswire)
08.11.18	Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development (Businesswire)
25.10.18	Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018 (Businesswire)
25.09.18	Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis (Businesswire)
19.09.18	Aurinia to Participate in Upcoming Investor Conferences (Businesswire)
28.08.18	Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 (Businesswire)
09.08.18	Aurinia Reports Second Quarter Financial Results and Operational Highlights (Businesswire)
11.07.18	Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome (Businesswire)
25.06.18	Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin (Businesswire)
22.06.18	Aurinia Announces Results of Annual General Meeting (Businesswire)
10.05.18	Aurinia Reports First Quarter Financial Results and Operational Highlights (Businesswire)
10.05.18	Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis (Businesswire)
01.05.18	Aurinia Pharmaceuticals to Release First Quarter 2018 Financial Results on May 10, 2018 (Businesswire)
25.04.18	Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018 (Businesswire)
02.04.18	Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018 (Businesswire)
15.03.18	Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights (Businesswire)
28.02.18	Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 (Businesswire)
22.02.18	Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors (Businesswire)
20.02.18	Aurinia Named Company of the Year by LifeSciences BC (Businesswire)
14.02.18	Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program (Businesswire)
08.02.18	Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors (Businesswire)
06.02.18	Aurinia to Present at Leerink Partners 7th Annual Global Healthcare Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Aurinia Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten